Medical device company Nurami Medical, a developer of next-generation regenerative solutions for soft tissue repair, on Monday reported the successful completion of Phase 1 of its EIC-funded grant for Artifix, a synthetic, biomimetic, dural repair adhesive patch, its second portfolio product.

Nurami said that during this phase it achieved crucial milestones including preclinical testing completion, technical file submission to EU regulators, and initial trial-country approvals. This paves the way toward First-in-Human (FiH) clinical trial approvals, projected by the end of 2025 with FiH commencement expected shortly thereafter.

The company has also started preliminary marketing and clinical engagement efforts, including discussions with leading neurosurgical KOLs across Europe and the United States, and participation in international neurosurgical conferences to strengthen early awareness and gather expert feedback.

With these achievements, Nurami has now secured Phase 2 funding under the European Innovation Council (EIC) programme.

Preliminary sales of ArtiFascia, Nurami's first portfolio product, an FDA cleared, sutureable, synthetic, biomimetic, dural repair graft that integrates proprietary bioengineered polymers, have commenced in the United States.